Projects

Can Cell-Free DNA (cfDNA) Serve as a Biomarker for Kidney Injury in Children? A Prospective Pilot Observational Study

Project Description

Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation. Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.

Project Duration

2026 - 2028

Project Lead

Dr. Arpana Iyengar

Authors

Dr. Arpana Iyengar, Dr. Jyoti S Prabhu & Dr. Soumya Reddy

Project Status

ongoing